By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
First-generation antipsychotic thioridazine was previously used extensively to treat schizophrenia and psychosis. It is a member of the phenothiazine medication class.
Certain mental/mood disorders are treated with this medicine (such as schizophrenia). You can participate in daily life and think more clearly and calmly thanks to this drug. Additionally, it can lessen hostility and the urge to harm others while also assisting those who are at risk of suicide.
Your negative thoughts and hallucinations may lessen with its assistance. Thioridazine is a member of the phenothiazine drug subclass.
Negative effects-It’s possible to experience headaches, blurred vision, constipation, problems urinating, dizziness, lightheadedness, and drowsiness. If any of these side effects persisted or worsened.
CYP2D6 metabolises thioridazine, a racemic chemical with two enantiomers, producing (S)- and (R)-thioridazine-2-sulfoxide, also known as mesoridazine, and (S)- and (R)-thioridazine-5-sulfoxide.
Sulforidazine is produced via the metabolism of mesoridazine. Thioridazine inhibits the enzymes CYP1A2 and CYP3A4.
Global THIORIDAZINE market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The impact of the thioridazine dopamine receptor antagonist on mouse breast cancer. Using a mouse breast cancer model, thioridazine’s anti-tumor effectiveness was evaluated.
Flow cytometry (FCM) and the MTT assay were used to examine cell death and proliferation in vitro, respectively. Following treatment with thioridazine, Western blot analysis was used to evaluate the levels of Akt, phosphorylated (p)Akt, STAT3, pSTAT3, and p65 in tumour cells.
In the tumour sections, the Ki67 index and the number of apoptotic cells that were TUNEL-positive for terminal deoxynucleotidyl transferase were measured.
Thioridazine was discovered to have dose- and time-dependent effects on tumour development, tumour cell proliferation, and the induction of apoptosis in vitro.
Additionally, it was shown that thioridazine significantly reduced tumour growth and cause apoptosis in vitro in a dose- and time-dependent way.
The lower Ki67 index and rise in TUNEL-positive cells were additional indicators that thioridazine significantly reduced tumour growth and induced tumour cell apoptosis in vivo.
Additionally, thioridazine was found to produce anti-tumor effects via altering the tumour stroma, limit angiogenesis in the tumour microenvironment, and block activation of the canonical nuclear factor light chain enhancer of activated B cells pathway.
